Table 4.

Mean CCA IMT in right and left side in all SLE group and controls related to included variables.

Variables	Controls: CCA IMT (n = 60)				All SLE: CCA IMT (n = 60)
	Right CCA		Left CCA		Right CCA		Left CCA
	B	P	B	P	B	P	B	P
Age	7.95	0.014	2.78	0.37	0.01	0.91	0.14	0.26
Female gender	–110.64	0.36	72.60	0.51	–2.83	0.48	–5.14	0.20
Duration of SLE	0	0	0	0	0.15	0.31	0.35	0.02
SDI score	0	0	0	0	0.35	0.77	3.07	0.01
SLEDAI-2K	0	0	0	0	0.30	0.65	0.04	0.95
Traditional risk factors and laboratory data
BMI (kg/m2)	11.6	0.30	16.42	0.12	–0.16	0.64	–0.30	0.37
Ever smoker (former or current)	0	0	0	0	–1.05	0.74	–1.10	0.74
Systolic blood pressure	8.60	0.002	3.03	0.26	–0.03	0.76	0.10	0.25
Diastolic blood pressure	11.22	0.014	2.75	0.53	–0.01	0.95	0.19	0.16
Raynaud	–105.00	0.32	–149.94	0.11	–0.87	0.78	0.58	0.85
Estimated glomerular filtration rate	0	0	0	0	–0.04	0.68	0.10	0.25
Total cholesterol	21.21	0.53	34.38	0.27	1.37	0.32	3.07	0.03
High-density lipoprotein (HDL)	138.84	0.14	5.24	0.95	0.02	1.00	5.83	0.07
Low-density lipoprotein (LDL)	3.10	0.94	51.04	0.17	0.06	0.52	1.18	0.48
Triglycerides (TG)	19.14	0.77	–17.60	0.77	3.10	0.09	4.81	0.01
High-sensitivity CRP	–9.26	0.40	–6.30	0.53	–0.10	0.84	0.26	0.59
Medical treatment, ongoing
Antimalarial agents	0	0	0	0	–5.98	0.18	–2.56	0.58
Glucocorticoid therapy	0	0	0	0	–3.80	0.16	–0.10	0.70
Warfarin therapy	0	0	0	0	–1.55	0.66	–1.36	0.70
Antiplatelet therapy	0	0	0	0	–5.34	0.12	2.76	0.44
Statin therapy	0	0	0	0	–4.42	0.37	–4.80	0.34
DMARD therapy	0	0	0	0	1.60	0.55	3.75	0.17

APS: Antiphospholipid syndrome; CRP: C-reactive protein; BMI: body mass index; DMARDs: disease modifying anti-rheumatic drugs; LN: lupus nephritis; SDI: SLICC/ACR damage index; SLE: systemic lupus erythematosus.

Notes: Statistically significant associations shown in bold.